Please assess the completion status of the following clinical trial:

Trial Title: Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ECOG performance status≤2；~2. Cytologically or pathologically confirmed stage IV NSCLC ( controlled pleural effusion will be eligible) with active EGFR mutation;~3. Estimated survival time more than 3 months;~4. Age older than 18 years and under 75 years;~5. Adequate bone marrow, hepatic, and renal function;AST and ALT≤2.5 times the highest reference value when not associated with hepatic metastases, or ≤5 times when hepatic metastases occur;~6. Without history of therapy for primary and metastatic disease;~7. With pleural effusion but can be controlled;~8. Asymptomatic bone metastases without treatment;~9. Based on fusion images of 4DCT MIP sketch tumors and lymph nodes, and limit the mean lung dose: V20≤25%，V30≤18%，MLD≤14Gy，V5≤60%;~10. M1a or M1b for metastases, and the number of the distant lesions ≤10；~11. Voluntary to participate in this clinical trial and sign the consent form.~Exclusion Criteria:~1. Patients with serious functional damage of important organs;~2. Patients diagnosed adequately with other malignant tumors;~3. Pregnant or lactating women;~4. Patients in an active period of acute or chronic infectious diseases;~5. Patients who are allergic to any drugs or people with allergies;~6. With brain metastases;~7. With bone metastases needing radiotherapy;~8. Patients who participate in other clinical trials concurrently;~9. Uncontrolled pleural effusion which may intervene the radiotherapy to primary tumor in lung;~10. The number of the distant lesions\>10；~11. Patients who are considered not eligible for the trial after evaluation by investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EGFR-TKIs combined with radiotherapy (Type: EXPERIMENTAL): EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.

Based on this trial design, predict the completion outcome and termination type (if applicable).